tiprankstipranks
Trending News
More News >
Haemonetics (HAE)
:HAE

Haemonetics (HAE) AI Stock Analysis

Compare
398 Followers

Top Page

HA

Haemonetics

(NYSE:HAE)

Rating:76Outperform
Price Target:
$76.00
▲(8.43%Upside)
Haemonetics shows strong financial performance with a positive growth trajectory, supported by strategic initiatives and leadership changes. Despite technical resistance and valuation concerns, the company’s guidance and operational strategies contribute positively to its overall outlook.
Positive Factors
Market Share Growth
The outlook looks bright as the company captures material share, benefits from continued pricing gains, and collections improve.
Operational Efficiency
The company delivered a 24.9% adjusted operating margin in the quarter and 24.0% for FY/25, looking to add another 200-300 bps in FY/26.
Revenue and Earnings Performance
Haemonetics generated $330.6 million in revenue, exceeding the consensus estimate of $329.4 million.
Negative Factors
Guidance and Market Expectations
Management provided FY26 revenue and EPS guidance that was below consensus at the midpoints.
Plasma Business Performance
The plasma business declined 9.1% on a reported basis and was down 8.9% organically.
Stock Performance Concerns
The stock has seen a steady decline due to concerns like slowing base plasma collections and the rate of VASCADE XL uptake.

Haemonetics (HAE) vs. SPDR S&P 500 ETF (SPY)

Haemonetics Business Overview & Revenue Model

Company DescriptionHaemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
How the Company Makes MoneyHaemonetics makes money primarily through the sale of its medical devices and software solutions to blood banks, plasma collection centers, and hospitals. The company's revenue streams include the sale of automated blood collection systems, blood processing equipment, and related consumables that are essential for the operation of these devices. Additionally, Haemonetics generates income from software licensing and support services, which provide critical data management and operational efficiencies for its clients. Strategic partnerships and long-term contracts with healthcare providers and organizations further bolster the company's revenue as these collaborations often involve the integration of Haemonetics' technology into large-scale blood management operations.

Haemonetics Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q4-2025)
|
% Change Since: 9.09%|
Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment Neutral
The earnings call presented a balanced view with strong revenue growth in the hospital segment and significant margin expansion, but it also faced challenges with the decline in Plasma revenue due to CSL transition and ongoing issues in China's market.
Q4-2025 Updates
Positive Updates
Strong Revenue Growth in Hospital Segment
Hospital revenue grew 12% in Q4 and 24% in fiscal 2025 on a reported basis, with organic growth of 9% and 12%, respectively.
Impressive Margin Expansion
Adjusted gross margin increased by 620 basis points in Q4 to 60.2% and by 300 basis points for fiscal 2025 to 57.4%.
Significant Plasma Revenue Growth Ex-CSL
Excluding CSL, Plasma revenue grew 11% in Q4 and 5% for fiscal 2025.
Share Buyback Program
Executed a $150 million share buyback, repurchasing approximately 2.4 million shares, and announced a new $500 million share repurchase program.
Enhanced Profitability and Earnings Growth
Fourth quarter adjusted net income was $61.6 million, up 34%, while adjusted earnings per diluted share was $1.24, up 39%.
Negative Updates
Plasma Revenue Decline Due to CSL Transition
Plasma revenue declined 9% in Q4 and 6% in fiscal 2025 due to the planned CSL transition.
Decline in Blood Center Revenue
Blood Center revenue declined 22% in Q4 and 8% in fiscal 2025 due to the Whole Blood divestiture.
Challenges in China's Market
Continued market challenges in China, affecting performance in the Hemostasis Management segment.
Vascular Closure Challenges
Legacy VASCADE business saw a decline, with VASCADE representing less than 15% of Vascular Closure revenue.
Company Guidance
During the Q4 2025 earnings call, Haemonetics Corporation provided extensive guidance for fiscal year 2026, highlighting several key metrics and projections. The company anticipates total organic revenue growth of 6% to 9%, excluding CSL, driven by strong performance in its Plasma and Hospital businesses. In the Hospital segment, revenue growth is projected to be between 8% and 11%, with significant contributions expected from both Interventional Technologies and Blood Management Technologies. Specifically, Vascular Closure revenue is forecasted to grow double-digit, supported by an 8.6% growth in addressable access sites in electrophysiology (EP) in the U.S. The company expects continued double-digit growth in Hemostasis Management and Transfusion Management within Blood Management Technologies. In Plasma, excluding CSL, an organic growth of 11% to 14% is anticipated, primarily fueled by U.S. share gains and technology adoption. The adjusted operating margin is projected to improve by 200 to 300 basis points, reaching 26% to 27%, with adjusted earnings per diluted share expected to be in the range of $4.70 to $5. Additionally, the guidance includes considerations for a $0.20 adjusted EPS impact from tariffs, and the adjusted tax rate is expected to increase to approximately 24.5%. The company forecasts free cash flow in fiscal 2026 to be between $160 million and $200 million, with a conversion ratio exceeding 70%.

Haemonetics Financial Statement Overview

Summary
Haemonetics demonstrates strong financial performance with notable revenue growth, improved gross and net profit margins, and effective cost management. The balance sheet shows reduced leverage and a solid equity position, while cash flow is robust with efficient cash management practices.
Income Statement
85
Very Positive
Haemonetics has demonstrated consistent revenue growth with a notable increase from $993 million in 2022 to $1.36 billion in 2025, reflecting a strong upward trend. The gross profit margin has improved to 55.04%, indicating efficient cost management. The net profit margin has also strengthened to 12.32%, showcasing enhanced profitability. Additionally, the EBIT and EBITDA margins have shown positive growth, contributing to overall financial health.
Balance Sheet
78
Positive
The company's debt-to-equity ratio has improved significantly with a reduction in total debt from $808 million in 2024 to $304 million in 2025, reflecting a stronger equity position. The equity ratio of 33.48% implies a stable financial structure, while the return on equity of 20.42% indicates effective utilization of equity capital. Overall, the balance sheet shows a solid financial position, though there remains room for improving the equity ratio further.
Cash Flow
82
Very Positive
Haemonetics has experienced positive free cash flow growth with an increase from $115 million in 2024 to $142 million in 2025. The operating cash flow to net income ratio stands at 1.08, indicating effective cash generation relative to profit. The free cash flow to net income ratio of 0.85 supports the company's ability to generate cash after capital expenditures. Overall, the cash flow statement reflects a healthy cash position and efficient cash management practices.
Breakdown
Mar 2025Mar 2024Jun 2023Jun 2022Jun 2021
Income StatementTotal Revenue
1.36B1.31B1.17B993.20M870.46M
Gross Profit
748.96M691.55M615.10M505.50M397.84M
EBIT
221.82M164.88M156.03M80.75M57.96M
EBITDA
221.82M265.58M249.34M178.50M142.25M
Net Income Common Stockholders
167.68M117.56M115.40M43.38M79.47M
Balance SheetCash, Cash Equivalents and Short-Term Investments
306.76M178.80M284.47M259.50M192.31M
Total Assets
2.45B2.20B1.93B1.86B1.82B
Total Debt
303.56M807.79M765.89M773.59M707.61M
Net Debt
-3.21M628.99M481.42M514.09M515.30M
Total Liabilities
1.63B1.24B1.12B1.11B1.09B
Stockholders Equity
820.84M959.96M818.00M749.42M731.67M
Cash FlowFree Cash Flow
142.45M115.45M162.87M75.75M71.77M
Operating Cash Flow
181.72M181.75M273.06M172.26M108.81M
Investing Cash Flow
-161.90M-322.39M-143.79M-86.34M-425.44M
Financing Cash Flow
108.82M38.16M-100.36M-15.75M367.45M

Haemonetics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price70.09
Price Trends
50DMA
65.12
Positive
100DMA
65.37
Positive
200DMA
72.08
Negative
Market Momentum
MACD
1.51
Negative
RSI
57.39
Neutral
STOCH
55.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAE, the sentiment is Neutral. The current price of 70.09 is above the 20-day moving average (MA) of 69.23, above the 50-day MA of 65.12, and below the 200-day MA of 72.08, indicating a neutral trend. The MACD of 1.51 indicates Negative momentum. The RSI at 57.39 is Neutral, neither overbought nor oversold. The STOCH value of 55.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HAE.

Haemonetics Risk Analysis

Haemonetics disclosed 37 risk factors in its most recent earnings report. Haemonetics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Haemonetics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
HAHAE
76
Outperform
$3.37B21.1318.83%3.95%44.09%
ATATR
73
Outperform
$9.98B27.6415.15%1.19%0.34%17.27%
70
Outperform
$14.43B27.3411.77%1.66%21.95%
BDBDX
68
Neutral
$49.36B32.865.97%2.42%5.84%15.12%
68
Neutral
$3.25B-4.62%7.19%-56.19%
TFTFX
58
Neutral
$5.30B37.803.48%1.13%0.29%-48.98%
54
Neutral
$5.38B3.27-45.10%3.30%16.81%0.02%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HAE
Haemonetics
70.09
-15.50
-18.11%
ATR
AptarGroup
151.16
6.09
4.20%
BDX
Becton Dickinson
172.21
-56.07
-24.56%
HOLX
Hologic
64.75
-6.68
-9.35%
ICUI
ICU Medical
132.04
13.53
11.42%
TFX
Teleflex
119.93
-84.12
-41.23%

Haemonetics Corporate Events

Business Operations and StrategyFinancial Disclosures
Haemonetics Approves Strategic Alignment Initiative in May 2025
Positive
May 8, 2025

In May 2025, Haemonetics‘ Board of Directors approved a strategic market and regional alignment initiative aimed at enhancing operational performance and reducing costs. This initiative is expected to incur restructuring charges of approximately $20 million, with anticipated annual savings of $30 million upon completion by the end of fiscal 2027. The company reported strong financial results for fiscal 2025, with a 4% increase in annual revenue to $1.361 billion and significant improvements in earnings and cash flow. Despite a decline in fourth-quarter revenue, Haemonetics achieved record margin expansion and operating income growth, driven by its hospital business and strategic pricing initiatives.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.